Scholarlink

<p>Colorectal cancer (CRC) remains a leading cause of cancer-related morbidity and mortality worldwide, and conventional therapies are often limited by low efficacy and severe side effects. Emodin (EO), a natural anthraquinone compound, exhibits notable anticancer activity but is hindered by poor stability, low bioavailability, and potential toxicity. To overcome these limitations, we developed a pH/ATP-responsive nanoplatform by coordinating EO with Fe(Ⅲ) (EO–Fe), encapsulating the complex within Zeolitic Imidazolate Framework-90 nanoparticles (ZIF-90 NPs), and functionalizing the surface with fibronectin (FN) to obtain EO–Fe@ZIF-90–FN NPs. The nanocarrier exhibited favorable physicochemical properties, good biocompatibility, and controlled release of EO and Fe under acidic and ATP-rich conditions that mimic the tumor microenvironment. In vitro, EO–Fe@ZIF-90–FN NPs significantly inhibited the proliferation and migration of SW480 and HCT-116 cells and promoted apoptosis. Mechanistic studies revealed that EO–Fe@ZIF-90–FN NPs induced ferroptosis by regulating mitochondrial dysfunction. In vivo, EO–Fe@ZIF-90–FN markedly suppressed tumor growth in CRC xenograft models. These findings demonstrate that EO–Fe@ZIF-90–FN NPs exert potent antitumor activity by inducing ferroptosis and mitochondrial dysfunction, providing a promising nanotherapeutic strategy for CRC treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Fibronectin-modified pH/ATP-responsive ZIF-90 nanoparticles induce ferroptosis in colorectal cancer via mitochondrial dysfunction

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月12日

查看全文
  • Shuyi Wen,
  • Meisi Lin,
  • Danxi Yan,
  • Mingxia Chen,
  • Renkai Li,
  • Aimei Li,
  • Jiamin Lu,
  • Ruoxi Chen,
  • Zexuan Yang,
  • Fei Gao,
  • Jieshu You

摘要

Colorectal cancer (CRC) remains a leading cause of cancer-related morbidity and mortality worldwide, and conventional therapies are often limited by low efficacy and severe side effects. Emodin (EO), a natural anthraquinone compound, exhibits notable anticancer activity but is hindered by poor stability, low bioavailability, and potential toxicity. To overcome these limitations, we developed a pH/ATP-responsive nanoplatform by coordinating EO with Fe(Ⅲ) (EO–Fe), encapsulating the complex within Zeolitic Imidazolate Framework-90 nanoparticles (ZIF-90 NPs), and functionalizing the surface with fibronectin (FN) to obtain EO–Fe@ZIF-90–FN NPs. The nanocarrier exhibited favorable physicochemical properties, good biocompatibility, and controlled release of EO and Fe under acidic and ATP-rich conditions that mimic the tumor microenvironment. In vitro, EO–Fe@ZIF-90–FN NPs significantly inhibited the proliferation and migration of SW480 and HCT-116 cells and promoted apoptosis. Mechanistic studies revealed that EO–Fe@ZIF-90–FN NPs induced ferroptosis by regulating mitochondrial dysfunction. In vivo, EO–Fe@ZIF-90–FN markedly suppressed tumor growth in CRC xenograft models. These findings demonstrate that EO–Fe@ZIF-90–FN NPs exert potent antitumor activity by inducing ferroptosis and mitochondrial dysfunction, providing a promising nanotherapeutic strategy for CRC treatment.